Sclar David A, Robison Linda M, Skaer Tracy L
Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, WA 99164-6510, USA.
Headache. 2008 Jan;48(1):126-9. doi: 10.1111/j.1526-4610.2007.00964.x. Epub 2007 Nov 13.
To discern the prevalence of concomitant use of a triptan and a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake inhibitor (SNRI) in the USA.
In July, 2006, the US Food and Drug Administration warned patients and health-care professionals to be aware that use of a triptan in combination with an SSRI or an SNRI may result in a potentially life-threatening problem known as serotonin syndrome.
We used weighted data from the US National Ambulatory Medical Care Survey for years 2003 and 2004 to derive national estimates of the number of office-based visits documenting concomitant use of a triptan and an SSRI or an SNRI.
During the time frame 2003-04, an annualized mean of 3,874,367 patients were prescribed a triptan, and 50,402,149 patients were prescribed an SSRI or an SNRI. An annualized mean of 694,276 patients were simultaneously prescribed or continued use of a triptan along with an SSRI or SNRI.
Our study documents that 1.3% of patients prescribed a triptan or an SSRI or an SNRI were prescribed the potentially fatal combination. While this is a small fraction overall, the actual number of patients on a nationwide basis is significant (n=694,276).
了解在美国曲坦类药物与选择性5-羟色胺再摄取抑制剂（SSRI）或选择性5-羟色胺/去甲肾上腺素再摄取抑制剂（SNRI）联合使用的普遍性。
2006年7月，美国食品药品监督管理局警告患者和医疗保健专业人员，曲坦类药物与SSRI或SNRI联合使用可能会导致一种名为血清素综合征的潜在威胁生命的问题。
我们使用了2003年和2004年美国国家门诊医疗调查的加权数据，以得出关于记录曲坦类药物与SSRI或SNRI联合使用的门诊就诊人数的全国性估计。
在2003 - 2004年期间，平均每年有3,874,367名患者被处方使用曲坦类药物，50,402,149名患者被处方使用SSRI或SNRI。平均每年有694,276名患者同时被处方或继续使用曲坦类药物与SSRI或SNRI。
我们的研究表明，在被处方使用曲坦类药物、SSRI或SNRI的患者中，有1.3%的患者被处方了这种潜在致命的联合用药。虽然总体比例较小，但全国范围内的实际患者数量相当可观（n = 694,276）。
